Fibrillin-3 in the fetal ovary: Can it contribute to polycystic ovary syndrome?

Expert Review of Endocrinology and Metabolism

Volumn 7, Issue 1, 2012, Pages 31-34

  Abbott, David H ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

developmental programming; extracellular matrix; ovarian stroma remodeling; TGF

Indexed keywords

FIBRILLIN; FIBRILLIN 3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ALLELE; ANOVULATION; ARTICLE; COW; EPIGENETICS; FEMALE INFERTILITY; FIRST TRIMESTER PREGNANCY; GENOME; HAPLORHINI; HUMAN; INTRON; METABOLIC SYNDROME X; MORPHOLOGY; NONHUMAN; OVARY POLYCYSTIC DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 82955193673     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/eem.11.90     Document Type: Article

References (21)

1. Hatzirodos N, Bayne RA, Irving-Rodgers HF et al. Linkage of regulators of TGF-b activity in the fetal ovary to polycystic ovary syndrome. FASEB J. 25(7), 2256-2265 (2011).
2. Robertson I, Jensen S, Handford P. TB domain proteins: evolutionary insights into the multifaceted roles of fibrillins and LTBPs. Biochem J. 433(2), 263-276 (2011).
3. Sabatier L, Miosge N, Hubmacher D, Lin G, Davis EC, Reinhardt DP. Fibrillin-3 expression in human development. Matrix Biol. 30(1), 43-52 (2011).
4. Massam-Wu T, Chiu M, Choudhury R et al. Assembly of fibrillin microfibrils governs extracellular deposition of latent TGF beta. J. Cell Sci. 123(Pt 17), 3006-3018 (2010).
5. Sengle G, Ono RN, Sasaki T, Sakai LY. Prodomains of transforming growth factor beta (TGFbeta) superfamily members specify different functions: extracellular matrix interactions and growth factor bioavailability. J. Biol. Chem. 286(7), 5087-5099 (2011).
6. Jordan CD, Bohling SD, Charbonneau NL, Sakai LY. Fibrillins in adult human ovary and polycystic ovary syndrome: is fibrillin-3 affected in PCOS? J. Histochem. Cytochem. 58(10), 903-915 (2010).
7. Urbanek M, Woodroffe A, Ewens KG et al. Candidate gene region for polycystic ovary syndrome on chromosome 19p13.2. J. Clin. Endocrinol. Metab. 90(12), 6623-6629 (2005).
8. Stewart DR, Dombroski BA, Urbanek M et al. Fine mapping of genetic susceptibility to polycystic ovary syndrome on chromosome 19p13.2 and tests for regulatory activity. J. Clin. Endocrinol. Metab. 91(10), 4112-4117 (2006).
9. Tucci S, Futterweit W, Concepcion ES et al. Evidence for association of polycystic ovary syndrome in Caucasian women with a marker at the insulin receptor gene locus. J. Clin. Endocrinol. Metab. 86(1), 446-449 (2001).
10. Ewens KG, Stewart DR, Ankener W et al. Family-based analysis of candidate genes for polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 95(5), 2306-2315 (2010).
11. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19(1), 41-47 (2004).
12. Wild RA, Carmina E, Diamanti-Kandarakis E et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J. Clin. Endocrinol. Metab. 95(5), 2038-2049 (2010).
13. Prodoehl MJ, Hatzirodos N, Irving- Rodgers HF et al. Genetic and gene expression analyses of the polycystic ovary syndrome candidate gene fibrillin-3 and other fibrillin family members in human ovaries. Mol. Hum. Reprod. 15(12), 829-841 (2009).
14. Abbott DH, Barnett DK, Bruns CM, Dumesic DA. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? Hum. Reprod. Update 11(4), 357-374 (2005).
15. Padmanabhan V, Veiga-Lopez A. Developmental origin of reproductive and metabolic dysfunctions: androgenic versus estrogenic reprogramming. Semin. Reprod. Med. 29(3), 173-186 (2011).
16. Shikanov A, Smith RM, Xu M, Woodruff TK, Shea LD. Hydrogel network design using multifunctional macromers to coordinate tissue maturation in ovarian follicle culture. Biomaterials 32, 2524-2531 (2011).
17. Xu N, Kwon S, Abbott DH et al. Epigenetic mechanism underlying the development of a polycystic ovary syndrome (PCOS)-like phenotype in prenatally androgenized rhesus monkeys. PLoS ONE 6, e27286 (2011).
18. Abbott DH, Barnett DK, Levine JE et al. Endocrine antecedents of polycystic ovary syndrome in fetal and infant prenatally androgenized female rhesus monkeys. Biol. Reprod. 79(1), 154-163 (2008).
19. Abbott DH, Bruns CR, Barnett DK et al. Experimentally induced gestational androgen excess disrupts glucoregulation in rhesus monkey dams and their female offspring. Am. J. Physiol. Endocrinol. Metab. 299(5), E741-E751 (2010).
20. Gaikwad AB, Gupta J, Tikoo K. Epigenetic changes and alteration of Fbn1 and Col3A1 gene expression under hyperglycaemic and hyperinsulinaemic conditions. Biochem. J. 432, 333-341 (2010).
21. Roos N, Kieler H, Sahlin L, Ekman-Ordeberg G, Falconer H, Stephansson O. Risk of adverse pregnancy outcomes in women with polycystic ovary syndrome: population based cohort study. BMJ 343, d6309 (2011).